- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06571045
A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME (BRUNELLO)
Un estudio fundamental de fase 2/3, aleatorizado, doble enmascarado, multicéntrico y de 3 brazos para evaluar la eficacia y seguridad del EYE103 intravítreo en comparación con el ranibizumab intravítreo (0,5 mg) en participantes con edema macular diabético
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)
In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm.
Approximately 960 participants will be entered in the study.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)
Approximately 960 participants will be entered in the study. Participants will be randomized 1:1:1 to receive low dose remigromig, high dose remigromig, or 0.5 mg ranibizumab, administered via intravitreal injection. In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval (PTI) algorithm. Throughout the 2-year study, subjects will be evaluated every 4 weeks, including measurement of Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA), examination by slit-lamp biomicroscopy, fundoscopy, and spectral domain optical coherence tomography (SD-OCT). Among other parameters, SD-OCT will be used to measure central subfield thickness (CST) in microns.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Frankfurt, Alemania, 60590
- Frankfurt, Germany
-
Hanover, Alemania, 30625
- Hanover, Germany
-
München, Alemania, 80336
- Munchen, Germany
-
Münster, Alemania, 48145
- Munster, Germany
-
-
-
-
-
CABA, Argentina, 1023
- Buenos Aires, Argentina
-
Córdoba, Argentina, X5000AAJ
- Ciudad de Cordoba, Argentina
-
-
Buenos Aires
-
CABA, Buenos Aires, Argentina, 1015
- Buenos Aires, Argentina
-
CABA, Buenos Aires, Argentina, 1120
- Buenos Aires, Argentina
-
CABA, Buenos Aires, Argentina, C1033AAW
- Buenos Aires, Argentina
-
Caba, Buenos Aires, Argentina, C1116ABA
- Caba, Buenos Aires, Argentina
-
-
Córdoba Province
-
Córdoba, Córdoba Province, Argentina, 5000
- Cordoba, Argentina
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000DSK
- Santa Fe, Argentina
-
-
Sante Fe
-
Rosario, Sante Fe, Argentina, 2000
- Santa Fe, Argentina
-
-
-
-
-
Albury, Australia, 2640
- Albury, Australia
-
Parramatta, Australia, 2150
- Parramatta, Australia
-
Sydney, Australia, 2000
- Sydney, Australia
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2000
- Sydney Retina Clinic
-
Sydney, New South Wales, Australia, 2135
- Sydney, Australia
-
-
-
-
-
Graz, Austria, 8036
- Graz, Austria
-
Innsbruck, Austria, 6020
- Innsbruck, Austria
-
Vienna, Austria, 1090
- Vienna, Austria
-
Vienna, Austria, 1140
- Vienna, Austria
-
-
-
-
-
Mladá Boleslav, Chequia, 293 01
- Mlada Boleslav, Czechia
-
Náchod, Chequia, 547 01
- Nachod, Czechia
-
Prague, Chequia, 1150/50
- Prague, Czechia
-
Prague, Chequia
- Prague, Czechia
-
-
-
-
-
Medellín, Colombia, 50016
- Medellin, Colombia
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 50021
- Medellin, Colombia
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 80002
- Barranquilla, Colombia
-
-
Columbia
-
Bogotá, Columbia, Colombia, 110231
- Bogota, Columbia
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombia, 760042
- Cali, Colombia
-
-
-
-
-
Osijek, Croacia, 31000
- Osijek, Croatia
-
-
-
-
-
Trebišov, Eslovaquia, 075 01
- Trebisov, Slovakia
-
Trenčín, Eslovaquia, 911 01
- Trencin, Slovakia
-
Žilina, Eslovaquia, 012 07
- Zilina, Slovakia
-
-
-
-
-
Barcelona, España, 08035
- Barcelona, Spain
-
Barcelona, España, 08021
- Barcelona, Spain
-
Barcelona, España, 08022
- Barcelona, Spain
-
Barcelona, España, 08195
- Barcelona, Spain
-
Santiago de Compostela, España, 15706
- Santiago de Compostela, Spain
-
Seville, España, 41009
- Sevilla, Spain
-
Zaragoza, España, 50009
- Zaragoza, Spain
-
-
Valencia
-
Burjassot, Valencia, España, 46100
- Valencia, Spain
-
-
-
-
Arizona
-
Scottsdale, Arizona, Estados Unidos, 85255
- Scottsdale
-
-
Arkansas
-
Fayetteville, Arkansas, Estados Unidos, 72703
- Fayetteville, Arkansas
-
Springdale, Arkansas, Estados Unidos, 72764
- Springdale, Arkansas
-
-
California
-
Bakersfield, California, Estados Unidos, 93309
- Bakersfield, CA
-
Glendale, California, Estados Unidos, 91204
- Glendale, CA
-
Modesto, California, Estados Unidos, 95356
- Modesto, CA
-
Mountain View, California, Estados Unidos, 94040
- Mountain View, CA
-
Redlands, California, Estados Unidos, 92374
- Redlands, CA
-
Sacramento, California, Estados Unidos, 95825
- Sacramento, CA
-
Sacramento, California, Estados Unidos, 95841
- Sacramento, CA
-
Santa Ana, California, Estados Unidos, 92705
- Santa Ana
-
-
Colorado
-
Colorado Springs, Colorado, Estados Unidos, 80909
- Colorado Springs, CO
-
Denver, Colorado, Estados Unidos, 80210
- Denver, Colorado
-
-
Connecticut
-
Danbury, Connecticut, Estados Unidos, 06810
- Danbury, CT
-
Manchester, Connecticut, Estados Unidos, 06042
- Manchester, CT
-
Waterford, Connecticut, Estados Unidos, 06385
- Waterford,CT
-
-
Florida
-
Deerfield Beach, Florida, Estados Unidos, 33064
- Deerfield Beach, FL
-
Fort Lauderdale, Florida, Estados Unidos, 33308
- Fort Lauderdale, FL
-
Fort Myers, Florida, Estados Unidos, 33912
- Fort Myers,FL
-
Gainesville, Florida, Estados Unidos, 32607
- Gainesville, FL
-
Orlando, Florida, Estados Unidos, 32806
- Orlando, Florida
-
Plantation, Florida, Estados Unidos, 33324
- Plantation, FL
-
Sarasota, Florida, Estados Unidos, 34232
- Sarasota, FL
-
St. Petersburg, Florida, Estados Unidos, 33711
- Saint Petersburg, FL
-
Tallahassee, Florida, Estados Unidos, 32308
- Tallahassee, FL
-
Tampa, Florida, Estados Unidos, 33609-4614
- Tampa, FL
-
Tampa, Florida, Estados Unidos, 33617
- Tampa, FL
-
Winter Haven, Florida, Estados Unidos, 33880
- Winter Haven, FL
-
-
Illinois
-
Lemont, Illinois, Estados Unidos, 60439
- Lemont, IL
-
Springfield, Illinois, Estados Unidos, 62702
- Springfield, Illinois
-
-
Iowa
-
West Des Moines, Iowa, Estados Unidos, 50266
- West Des Moines, IA
-
-
Kansas
-
Lenexa, Kansas, Estados Unidos, 66215
- Lenexa, Kansas
-
Wichita, Kansas, Estados Unidos, 67214
- Wichita, Kansas
-
-
Maine
-
Portland, Maine, Estados Unidos, 04101
- Portland, Maine
-
-
Maryland
-
Hagerstown, Maryland, Estados Unidos, 21740
- Hagerstown, MD
-
-
Massachusetts
-
Springfield, Massachusetts, Estados Unidos, 01107
- Springfield,MA
-
-
Michigan
-
Grand Rapids, Michigan, Estados Unidos, 49546
- Grand Rapids, Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55435
- Minneapolis, MN
-
-
Mississippi
-
Madison, Mississippi, Estados Unidos, 39110
- Madison, MS
-
-
New Jersey
-
Bloomfield, New Jersey, Estados Unidos, 07003
- Bloomfield, NJ
-
Cherry Hill, New Jersey, Estados Unidos, 08034
- Cherry Hill, NJ
-
-
New York
-
Liverpool, New York, Estados Unidos, 13088
- Liverpool, NY
-
Oceanside, New York, Estados Unidos, 11572
- Oceanside, NY
-
Rochester, New York, Estados Unidos, 14620
- Rochester, NY
-
-
North Carolina
-
Asheville, North Carolina, Estados Unidos, 28803
- Asheville, NC
-
Hickory, North Carolina, Estados Unidos, 28602
- Hickory, NC
-
Wake Forest, North Carolina, Estados Unidos, 27587
- Wake Forest, MC
-
Winston-Salem, North Carolina, Estados Unidos, 27103
- Winston Salem, NC
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44122
- Cleveland, Ohio
-
Cleveland, Ohio, Estados Unidos, 44130
- Cleveland, OH
-
Youngstown, Ohio, Estados Unidos, 44505
- Youngstown, Ohio
-
-
Oklahoma
-
Edmond, Oklahoma, Estados Unidos, 73013
- Edmond, OK
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97221
- Portland, OR
-
Springfield, Oregon, Estados Unidos, 97477
- Springfield, Oregon
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Estados Unidos, 18017
- Bethlehem, PA
-
Erie, Pennsylvania, Estados Unidos, 16507
- Erie, PA
-
-
South Carolina
-
Beaufort, South Carolina, Estados Unidos, 29902
- Beaufort, SC
-
Florence, South Carolina, Estados Unidos, 29501
- Florence, SC
-
Ladson, South Carolina, Estados Unidos, 29456
- Ladson, SC
-
West Columbia, South Carolina, Estados Unidos, 29169
- West Columbia, SC
-
-
Tennessee
-
Germantown, Tennessee, Estados Unidos, 38138
- Germantown, TN
-
Hixson, Tennessee, Estados Unidos, 37343
- Hixson, Tennessee
-
Johnson City, Tennessee, Estados Unidos, 37604
- Johnson City, Tennessee
-
Knoxville, Tennessee, Estados Unidos, 37922
- Knoxville, TN
-
Nashville, Tennessee, Estados Unidos, 37203
- Nashville, TN
-
-
Texas
-
Abilene, Texas, Estados Unidos, 79606
- Abilene, TX
-
Amarillo, Texas, Estados Unidos, 79109
- Amarillo, TX
-
Amarillo, Texas, Estados Unidos, 79106
- Amarillo, TX
-
Arlington, Texas, Estados Unidos, 76012
- Arlington, TX
-
Austin, Texas, Estados Unidos, 78705
- Austin, TX
-
Beaumont, Texas, Estados Unidos, 77707
- Beaumont, TX
-
Bellaire, Texas, Estados Unidos, 77401
- Bellaire, TX
-
Dallas, Texas, Estados Unidos, 75231
- Dallas, TX
-
Fort Worth, Texas, Estados Unidos, 76104
- Fort Worth, TX
-
Katy, Texas, Estados Unidos, 77494
- Katy, TX
-
Plano, Texas, Estados Unidos, 75075
- Plano, TX
-
Round Rock, Texas, Estados Unidos, 78681
- Round Rock, TX
-
San Antonio, Texas, Estados Unidos, 78240
- San Antonio, TX
-
Schertz, Texas, Estados Unidos, 78154
- Schertz, Texas
-
The Woodlands, Texas, Estados Unidos, 77384
- The Woodlands, TX
-
Willow Park, Texas, Estados Unidos, 76087
- Willow Park, TX
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84107
- Salt Lake City, Utah
-
-
Virginia
-
Lynchburg, Virginia, Estados Unidos, 24502
- Lynchburg, VA
-
Richmond, Virginia, Estados Unidos, 23235
- Richmond, Virginia
-
-
Washington
-
Spokane, Washington, Estados Unidos, 99204
- Spokane, WA
-
-
-
-
-
Créteil, Francia, 94010
- Creteil, France
-
Lyon, Francia, 69004
- Lyon, France
-
Marseille, Francia, 13008
- Marseille, France
-
Paris, Francia, 75006
- Paris, France
-
Paris, Francia, 75015
- Paris, France
-
Paris, Francia, 75019
- Paris, France
-
Saint-Cyr-sur-Loire, Francia, 37540
- Saint Cyr sur Loire, France
-
-
Cedex
-
Dijon, Cedex, Francia, 21079
- Cedex, France
-
-
-
-
-
Budapest, Hungría, H-1062
- Budapest, Hungary
-
Budapest, Hungría, H-1085
- Budapest, Hungary
-
Budapest, Hungría, H-1106
- Budapest, Hungary
-
Budapest, Hungría, H-1133
- Budapest, Hungry
-
Debrecen, Hungría, H-4032
- Debrecen, Hungary
-
Pécs, Hungría, H-7621
- Pecs, Hungary
-
Szeged, Hungría, H-6720
- Szeged, Hungary
-
Zalaegerszeg, Hungría, 8900
- Zalaegerszeg, Hungary
-
-
-
-
-
Be’er Ya‘aqov, Israel, 70300
- Beer Yakov, Israel
-
Haifa, Israel, 3436212
- Haifa, Israel
-
Jerusalem, Israel, 9112001
- Jerusalem, Israel
-
Petah Tikva, Israel, 49100
- Petah Tikva, Israel
-
Rehovot, Israel, 76100
- Rehovot, Israel
-
Tel Aviv, Israel, 6423906
- Tel Aviv, Israel
-
-
-
-
-
Bologna, Italia, 40138
- Bologna, Italy
-
Florence, Italia, 50139
- Firenze, Italy
-
Milan, Italia, 20122
- Milano, Italy
-
Milan, Italia, 20132
- Milano, Italy
-
Milan, Italia, 20157
- Milano, Italy
-
Roma, Italia, 00168
- Roma, Italy
-
Rome, Italia, 81.00133
- Rome, Italy
-
Udine, Italia, 33100
- Udine, Italy
-
-
-
-
-
Riga, Letonia, LV1002
- Riga, Latvia
-
Riga, Letonia, LV1006
- Riga, Latvia
-
-
-
-
-
Bialystok, Polonia, 15-866
- Bialystok, Poland
-
Bydgoszcz, Polonia, 85-309
- Bydgoszcz, Poland
-
Bydgoszcz, Polonia, 85-631
- Bydgoszcz, Poland
-
Gdansk, Polonia, 80-809
- Gdansk, Poland
-
Katowice, Polonia, 40-594
- Katowice, Poland
-
Krakow, Polonia, 31-501
- Krakow, Poland
-
Olsztyn, Polonia, 10-424
- Olsztyn, Poland
-
Tarnowskie Góry, Polonia, 42-600
- Tarnowskie Gory, Poland
-
-
Gdansk
-
Gdansk, Gdansk, Polonia, 80-809
- Gdansk, Poland
-
-
-
-
-
Coimbra, Portugal, 3000-548
- Coimbra, Portugal
-
Coimbra, Portugal, 3030-163
- Coimbra, Portugal
-
Porto, Portugal, 4200-319
- Porto, Portugal
-
-
-
-
PR
-
Arecibo, PR, Puerto Rico, 00612
- Arecibo, PR
-
-
-
-
-
Bradford, Reino Unido, BD9 6RJ
- Bradford, United Kingdom
-
Bristol, Reino Unido, BS1 2LX
- Bristol, UK
-
Liverpool, Reino Unido, L7 8YA
- Liverpool, United Kingdom
-
Sunderland, Reino Unido, SR2 9HP
- Sunderland, United Kingdom
-
Wolverhampton, Reino Unido, WV10 0QP
- Wolverhamptom, United Kingdom
-
-
Middlesex
-
London, Middlesex, Reino Unido, NW10 7NS
- London, UK
-
-
UnitedKingdom
-
York, UnitedKingdom, Reino Unido, YO10 4DZ
- York, United Kingdom
-
-
-
-
Turkey
-
Ankara, Turkey, Turquía (Türkiye), 06230
- Ankara, Turkey
-
Ankara, Turkey, Turquía (Türkiye), 06490
- Ankara, Turkey
-
Balçova, Turkey, Turquía (Türkiye), 35330
- Balcova, Turkey
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
- Be male or female ≥18 years of age.
- Have type 1 or type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) of ≤12%.
- Have a decrease in vision in the study eye determined by the investigator to be primarily the result of diabetic macular edema (DME).
Exclusion Criteria:
-
Be pregnant or breastfeeding
-
History of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening
-
Have any treatment for complications of cataract surgery with steroids or yttrium aluminum garnet (YAG) laser capsulotomy within 90 days of Screening
-
Are currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone)
-
If treatment-experienced for DME have a history of any of the following treatments within the noted time windows:
- Have had prior treatment in the study eye with 8 mg aflibercept (EYLEA HD) or faricimab (VABYSMO) within 120 days prior to the Screening visit in the study eye
- Have had an IVT with other anti-VEGF treatments (ranibizumab, bevacizumab, aflibercept [2 mg], brolucizumab, pegaptanib sodium) in the study eye within 90 days of the Screening visit
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Remigromig Low Dose Treatment Arm
Remigromig Low Dose Treatment Arm |
Remigromig is a humanized antibody formulated for intravitreal administration
Otros nombres:
|
|
Experimental: Remigromig High Dose Treatment Arm
Remigromig High Dose Treatment Arm |
Remigromig is a humanized antibody formulated for intravitreal administration
Otros nombres:
|
|
Comparador activo: Ranibizumab Treatment Arm
Ranibizumab Treatment Arm |
Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart
Periodo de tiempo: Baseline and Week 52
|
The change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented. |
Baseline and Week 52
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from Baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52
Periodo de tiempo: Baseline and Week 52
|
The change from baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52 will be presented. |
Baseline and Week 52
|
|
Superiority Hypothesis: Change from Baseline in ETDRS BCVA at Week 52
Periodo de tiempo: Baseline and Week 52
|
The Superiority Hypothesis: change from baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented. |
Baseline and Week 52
|
|
Time to Absence of Diabetic Macular Edema (DME)
Periodo de tiempo: Up to approximately Week 104
|
The time to absence of Diabetic Macular Edema (DME) defined as Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) of <300 μm will be presented. |
Up to approximately Week 104
|
|
Time to Gaining ≥15 ETDRS letters
Periodo de tiempo: Up to approximately Week 52
|
The time to gaining ≥15 letters on the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented. |
Up to approximately Week 52
|
|
Proportion of Participants with Resolution of Macular Leakage on FA at Week 24
Periodo de tiempo: Up to approximately Week 24
|
The proportion of participants with resolution of macular leakage on fluorescein angiography (FA), defined as 0 to 1 mm^2, at Week 24 will be presented. |
Up to approximately Week 24
|
|
Proportion of Participants Without Intraretinal and Subretinal Fluid at the Foveal Center on OCT at Week 52
Periodo de tiempo: Up to approximately Week 52
|
The proportion of participants without intraretinal and subretinal fluid at the foveal center on Optical Coherence Tomography (OCT) at Week 52 will be presented. |
Up to approximately Week 52
|
|
Change from Baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52
Periodo de tiempo: Baseline and Week 52
|
The change from baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52 will be presented. |
Baseline and Week 52
|
|
Proportion of Participants Achieving 20/40 or Better BCVA at Week 52
Periodo de tiempo: Up to approximately Week 52
|
The proportion of participants who achieve 20/40 or better Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented. |
Up to approximately Week 52
|
|
Number of Participants Who Experience an Ocular and/or Systemic Adverse Event (AE)
Periodo de tiempo: Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic AE will be reported. |
Up to approximately 104 Weeks
|
|
Number of Participants Who Experience an Ocular and/or Systemic Serious Adverse Event (SAE)
Periodo de tiempo: Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic serious adverse event (SAE) will be reported. |
Up to approximately 104 Weeks
|
|
Number of Participants Who Discontinue Study Treatment Due to an AE
Periodo de tiempo: Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported. |
Up to approximately 104 Weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Charles Miller, MD PhD, EyeBiotech Ltd.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- EYE-RES-102
- MK-3000-001 (Otro identificador: MSD)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .